Diacer

Quick links to important sections

Diacer

Method of action: Anti-Inflammatory, Antirheumatic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diacer

Quick Facts

Property Description
Active ingredient Diacerein (INN)
Form Hard capsule or tablet
Pharmacological class Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA)
Origin Semi-synthetic (Anthraquinone derivative)

Defining Diacer: Class and Composition

Diacer is a pharmaceutical preparation that contains the active ingredient Diacerein, which is classified as a Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA). This designation is given to agents that work over an extended period to influence the disease process itself, distinguishing it from fast-acting painkillers. Diacerein functions as a prodrug and is chemically categorized as a semi-synthetic anthraquinone derivative. The medicine is delivered through the oral route as a solid preparation, typically a capsule or tablet. Once administered, Diacerein is metabolized in the body into its active compound, rhein. This active ingredient has been the focus of numerous pharmacological studies supporting its classification and unique mechanism of action in joint health.


Diacerein's Role in Joint Health: Mechanism Group and General Purpose

The general purpose of Diacerein is to address the underlying pathology in degenerative joint conditions by modulating the biological signals responsible for joint tissue destruction. The active metabolite, rhein, selectively inhibits the production and activity of Interleukin-1 beta (IL-1beta), a key molecular messenger that promotes inflammation and cartilage breakdown. By mitigating the destructive effects of IL-1beta, the drug confers an anti-catabolic property that helps to slow the progressive degradation of the cartilage matrix. This sustained, structural mechanism defines its therapeutic goal: providing a long-term foundation for managing chronic joint health rather than offering rapid relief from acute symptoms.

What side effects are possible with Diacer?

Possible Side Effects and Safety Information

The official safety profile for Diacer (Diacerein) is primarily structured around effects on the gastrointestinal and hepatobiliary systems, as detailed in regulatory documents such as the European Summary of Product Characteristics (SmPC).


Frequency and Organ Systems

The most frequently documented adverse reactions are concentrated in the gastrointestinal tract. Diarrhoea and abdominal pain are classified as very common adverse reactions. Other common effects include frequent bowel movements, flatulence, and skin reactions such as pruritus, rash, or eczema. The occurrence of these common gastrointestinal effects is generally noted in regulatory texts to abate with continuing treatment.


Serious Adverse Reactions and Key Restrictions

Diacerein is associated with the risk of serious adverse reactions. These include cases of acute liver injury (sometimes with fatal outcome) and severe diarrhoea that can lead to dehydration and significant disorders of fluid and electrolyte balance, such as hypokalemia. Elevated hepatic enzymes in the serum are classified as uncommon effects, and acute liver injury often occurred during the first months of treatment, according to post-marketing data.

Regulatory authorities have established explicit constraints based on this safety profile:

  • Liver Disease: Use is a formal contraindication in patients with established liver disease or a history of liver disease.
  • Older Adults: Use is not recommended in patients aged 65 years and above due to the increased risk of severe diarrhoea and related complications.
  • Renal Impairment: Use is not recommended in individuals with severe renal failure (creatinine clearance less than 30 ml/min).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Diacerein (Diacer) overdose centers on the manifestations resulting from the intake of high doses and the required emergency response.


Documented Overdose Manifestations

The primary documented clinical sign associated with high-dose exposure is severe diarrhoea. This gastrointestinal manifestation carries the risk of severe, life-threatening outcomes due to subsequent physiological changes.

Severe diarrhoea can rapidly lead to significant dehydration and disorders of fluid and electrolyte balance, specifically hypokalaemia (low potassium). These metabolic and nutritional disturbances define the potential severity of an overdose situation.


Emergency Actions and Required Monitoring

In the event of a suspected overdose, regulatory guidance mandates that patients seek emergency medical treatment immediately. Treatment must be stopped and a physician contacted if diarrhoea occurs, particularly if severe. As no specific antidote is known, management of overdose is symptomatic.

Supportive measures are required for the correction of dehydration and electrolyte disorders. Monitoring is essential to manage these imbalances. Regulatory authorities note that elderly patients are at heightened risk for the severe complications of diarrhoea, necessitating caution.

Therapeutic Uses of Diacer

Therapeutic Indications

Diacer is primarily utilized for the management of symptoms associated with degenerative joint diseases. It belongs to a class of medications known as anthraquinones, which are characterized by their slow-acting approach to treating joint conditions. Unlike rapid-acting pain relievers, this medication is designed to address the underlying processes of joint degradation over time.

Osteoarthritis Management

The principal application of Diacer is the treatment of osteoarthritis, particularly affecting the hip and knee. It is indicated for patients who require long-term management of the symptoms associated with this condition. The medication works by inhibiting specific biological mediators that contribute to inflammation and the breakdown of cartilage within the joints.

Benefits and Mechanisms

Diacer offers several clinical benefits for individuals with chronic joint wear, focusing on improving the overall functional state of the affected areas.

  • Cartilage Protection: The medication helps in maintaining the integrity of joint structures by reducing the activity of enzymes that degrade the cartilaginous matrix.
  • Anti-inflammatory Properties: It modulates the production of interleukin-1, a primary protein involved in the inflammatory response and joint tissue destruction.
  • Symptomatic Relief: While the onset of action is gradual, consistent use is associated with a reduction in joint pain and an increase in mobility.
  • Carry-over Effect: One of the notable characteristics of this treatment is its sustained effect; the benefits often persist for several weeks even after the treatment cycle has been completed.

By targeting the inflammatory cycle within the synovium and cartilage, Diacer helps stabilize the joint environment, potentially slowing the progression of functional limitations caused by osteoarthritis.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Diacer

The eligibility for Diacer (Diacerein) is strictly defined by regulatory health authorities and is based on age, reproductive status, and pre-existing medical conditions, establishing an officially restricted patient population.

Absolute Contraindications (Must Not Be Used)

Condition / Population Status Rationale Focus
Liver Disease Contraindicated Current or history of hepatic impairment (liver disease).
Bowel Disease Contraindicated Inflammatory organic bowel diseases (e.g., Crohn's disease, ulcerative colitis).
Hypersensitivity Contraindicated Known allergy to Diacerein, its metabolite rhein, or anthraquinone derivatives.

Age and Life Stage Restrictions

  • Older Adults (65+ years): Not recommended due to increased risk of severe diarrhea and related complications, as specified by the European Medicines Agency (EMA).
  • Children and Adolescents (under 15 years): Not established and generally contraindicated; safety and efficacy are not defined for this age group.
  • Pregnancy and Breastfeeding: Must not be administered or prescribed.

Conditional Use

Patients with severe renal impairment (creatinine clearance <30 mL/min) have limited eligibility and must undergo a mandatory dose reduction for use to be considered.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Diacerein documents interactions classified by their effects on drug exposure and patient physiology. Co-administration with Antacids (containing aluminum, calcium, or magnesium) causes a significant pharmacokinetic interaction resulting in decreased digestive absorption of Diacerein. To manage this absorption issue, regulatory guidance mandates that Antacids must be administered separately by an interval of greater than 2 hours. Conversely, taking Diacerein with Food is officially documented to result in a pharmacokinetic interaction that increases its overall bioavailability and slightly delays absorption.

A critical pharmacodynamic concern involves the risk of hypokalemia (low potassium) secondary to Diacerein-associated diarrhea. For this reason, co-administration with Diuretics (Thiazides or Loop) and Cardiac Glycosides requires particular caution due to the combined potential to increase the risk of serious arrhythmia. Concomitant intake with Laxatives is officially stated to be avoided as it reinforces the diarrhea risk. An additive effect is also documented when Diacerein is combined with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Furthermore, a substance-specific restriction advises patients to limit their alcohol intake during treatment due to the potential for compounded risk of hepatotoxicity (liver injury).

Mechanism of Action

Modulating Pro-inflammatory Cytokine Production

Diacer functions as a non-competitive inhibitor and negative modulator within the signal transduction cascades of immune cells. Its primary biological targets are the regulatory components of the MAPK/ERK and PI3K/AKT kinase pathways that govern inflammatory transcription. By modulating these key kinases, the drug suppresses the phosphorylation and subsequent activation of transcription factors (e.g., NF-κB).

Interfering with Intracellular Signaling

This disruption of early molecular signaling steps significantly reduces the transcription and synthesis of primary pro-inflammatory cytokines, specifically Interleukin-1 beta (IL-1β) and Tumor Necrosis Factor-alpha (TNF-α). The resultant decrease in systemic cytokine concentration initiates a cascade leading to the attenuation of localized inflammatory responses and the modulation of afferent nociceptive pathways at peripheral tissue sites. This action influences the balance of signaling activity within the affected physiological systems.

Dosage and Administration Information

Diacer, containing the active ingredient Diacerein, is administered exclusively via the oral route as a 50 mg hard capsule. Use of the medicine follows a phased schedule. The initial administration period is 2 to 4 weeks, during which the standard dosage is 50 mg taken once daily. This regimen then progresses to the standard maintenance dose of 100 mg per day, which is split into two 50 mg doses taken twice daily for continuous, long-term management.

The proper administration conditions are strictly defined. The hard capsule must be swallowed intact and should not be opened or crushed. Furthermore, the medicine must be taken with food; for the maintenance phase, this means one dose should be taken with breakfast and the other with the evening meal.

Official labeling provides specific instructions regarding usage in certain populations. The medicine is not recommended for administration to patients aged 65 years and older. For individuals with severe renal impairment (Creatinine Clearance < 30 ml/min), the standard daily dosage must be halved to 50 mg once daily. The initiation of this treatment is generally reserved for specialists experienced in managing the underlying condition.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Diacer


Evidence for Symptom Management in Knee Osteoarthritis (OA)

A broad body of research, including Randomized Controlled Trials (RCTs) and subsequent Meta-analyses, has been studied in research exploring how symptoms change over time in patients with knee osteoarthritis. These studies primarily focused on adults and older adults diagnosed with the condition. The research explored outcomes related to physical discomfort and daily functioning.

The studies monitored patient-reported outcomes describing perceived discomfort, primarily using standardized scales to measure chronic joint pain and physical function/disability. Some meta-analyses described the measured changes in symptomatic outcomes as small in magnitude. What remains uncertain is the consistency of these findings, as evidence quality varies across studies.


Evidence for Symptom Management in Hip Osteoarthritis (OA)

Research has also examined Diacer in the context of hip osteoarthritis, primarily through RCTs. The research explored outcomes related to physical discomfort and functional capacity. Findings showed similar patterns of variability to those described for the knee, and findings were mixed.

For structural outcomes, such as monitoring the change in joint space width (JSN), some long-term studies reported measurements of change in joint space narrowing. However, these structural observations were described as being small in magnitude and primarily identified in research concerning the hip joint itself. The clinical relevance of the reported structural measurements is subject to scientific debate.


Unanswered Questions and Research Gaps

Diacer was studied for its use in long-term chronic therapy with follow-up durations up to three years. However, long-term outcomes are not fully established beyond the periods examined in controlled trials. A key area of uncertainty lies in the inconsistent findings and high variability observed across different studies. Furthermore, comparative evidence is lacking in some areas, and data remain insufficient for patients with certain co-occurring health conditions.

Frequently Asked Questions (FAQ)

Common questions about Diacer (FAQ)


Q: Are the side effects of Diacer usually temporary, or do they last a long time?

The official product information describes that the most frequently reported gastrointestinal side effects, such as loose stools or diarrhea, often lessen or abate with continued treatment.

This indicates that these common reactions may resolve as the body adjusts to the medicine over time.


Q: How long does it usually take to feel the effects of Diacer after starting treatment?

According to official documents, Diacer is classified as a symptomatic slow-acting medicine (SYSADOA).

Because of its specific profile, the full therapeutic effects may take several weeks to appear, with initial beneficial effects noted after 2 to 4 weeks of continuous use.


Q: Is it necessary to take Diacer at the exact same time every day?

Regulatory guidance advises that Diacer must be taken with food, which typically means once with breakfast and once with the evening meal in the maintenance phase.

For optimal results and to support the consistency of treatment, official product information suggests maintaining a consistent daily schedule around these mealtimes.


Q: What is the duration of treatment with Diacer typically recommended in studies?

After an initial starting period, treatment with Diacer is often intended for continuous, long-term management of the condition it addresses.

Clinical trials and research have examined the use of the medicine for extended periods, including durations up to three years.


Q: Does Diacer require regular blood tests or monitoring while taking it?

Due to the documented potential for acute liver injury and elevated hepatic enzymes, official regulatory documents state that monitoring for signs of liver problems is required during treatment.

This monitoring is performed to check for early signs of hepatic complications.


Q: Do the effects of Diacer vary based on a person's age or weight?

The official eligibility and administration conditions are strictly defined based on age, as the medicine is not recommended for those aged 65 and older.

Dosage adjustment is also required for patients with severe renal impairment. However, official documents do not specify dose variations based on a patient's body weight.


Q: Can taking Diacer affect my sleep patterns?

Regulatory-related documents indicate that there is no known evidence suggesting the medicine directly impacts typical sleep patterns.


Q: What happens if I forget to take a dose of Diacer?

The regulatory guidance addresses missed doses to ensure administration consistency.

Official product information states that if a dose is missed and it is nearly time for the next dose, the procedure is to skip the missed dose and continue with the regular schedule, rather than taking two doses.


Q: Can I stop taking Diacer suddenly if I feel better?

Official guidance advises immediate discontinuation and contact with a healthcare professional only in specific, severe cases, such as signs of liver damage or severe diarrhea.

In other situations, stopping the medicine prematurely may be associated with a recurrence of symptoms in the condition being managed.


Q: Are there any restrictions on driving or operating machinery while taking Diacer?

Regulatory-related documents describe the potential for dizziness or fatigue in some individuals.

Official documentation notes that patients should refrain from driving or operating heavy machinery until they know how the medicine affects them.


Q: Is it normal to feel a bit nauseous when first starting Diacer?

Nausea is listed in the official safety profile as a possible side effect of the medicine.

While it occurs less frequently than the very common reactions like diarrhea and abdominal pain, it is a documented potential occurrence.


Q: If I have a mild side effect, should I immediately stop taking Diacer?

Official regulatory guidance advises immediate discontinuation and contact with a healthcare professional only in specific, severe cases, like severe diarrhea or signs of liver damage.

The official documentation does not provide blanket instruction for discontinuing the medicine due to all mild side effects.


Q: Is Diacer available over-the-counter in any country?

According to patient information documents, the medicine is typically required to be purchased with a prescription.

It is prescribed by a registered medical practitioner.


Q: Do official documents mention any potential for Diacer to affect fertility?

Regulatory-related documents state that there is no known evidence suggesting the medicine directly affects fertility in either men or women.

How should Diacer be stored and disposed of?

How to Store and Dispose of Diacer (Diacerein)

Official regulatory information defines specific conditions for storing and disposing of Diacer capsules to maintain stability and ensure safety.

Storage Conditions:

The product must be stored at a temperature below 25 C in a cool and dry place. It is mandatory to keep the medicine away from heat and direct sunlight. The capsules must remain in their original containers and the container must be kept tightly closed. For child safety, the medicine should be stored locked up.

Disposal Requirements:

Disposal of unused or expired Diacer must be done in accordance with local, regional, and national regulations. To protect the environment, the product should not be released into public waters; regulatory guidelines advise adherence to procedures that avoid release to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diacer found in:

A-Z Index: